Jardiance Indications/Uses

Type 2 diabetes mellitus: Glycaemic control: Empagliflozin (Jardiance) is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.
Add-on combination therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
Prevention of cardiovascular death: Empagliflozin (Jardiance) is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Pharmacology: Pharmacodynamics: Clinical Trials under Actions).
To prevent cardiovascular deaths, Empagliflozin (Jardiance) should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.
Heart failure (HF): Empagliflozin (Jardiance) is indicated in adult patients with heart failure (NYHA class II-IV) independent of left ventricular ejection fraction, with or without type 2 diabetes mellitus: to reduce the risk of cardiovascular death and hospitalization for heart failure; to slow kidney function decline.